Cullinan Therapeutics

Company snapshot

Octagon is developing new medicines for autoimmune and inflammatory disease. The company is pioneering a selective immunomodulation approach based on glyco-immune checkpoint receptors that allows for precise targeting of disease-driving immune processes.

• 16 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 US patent(s) indexed to this assignee profile.
• 16 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cullinan Therapeutics. Not investment advice.

• Peer + 0 momentum

  Chongqing Precision Biotech

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  GSK Glaxo Smith

  TA overlap score 40

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 40

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 32.4

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Cellectar Biosciences

  TA overlap score 23.4

• Peer + 0 momentum

  Prelude Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for Cullinan Therapeutics.

1. Jun 8, 2026 Clinical update

   CLN-978-SL-101 — Phase 1

2. Jun 8, 2026 Clinical update

   CLN-619-001 — Phase 1

3. Jun 8, 2026 Clinical update

   CLN-049-002 — Phase 1

4. Jun 8, 2026 Clinical update

   CLN-978-SJ-101 — Phase 1

5. Jun 8, 2026 Clinical update

   CLN-978-RA-101 — Phase 1

View all clinical trial activity →

• What is Cullinan Therapeutics?

  Octagon Therapeutics is a biotech organization headquartered in Providence, USA. It trades on NYSE under ticker CGEM. Primary therapeutic focus areas include Advanced Solid Tumor, Sjogren's Disease, Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD), Non-Small Ce

• Is Cullinan Therapeutics publicly traded?

  Yes. Cullinan Therapeutics is listed with ticker CGEM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cullinan Therapeutics develop or market?

  We link 14 drug profile(s) where Cullinan Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cullinan-therapeutics#company-drugs.

• What are the latest developments for Cullinan Therapeutics?

  In the last 12 months our linked public records show 16 trial program update(s) and 2 US patent grant(s) tied to this profile.

• What therapeutic areas does Cullinan Therapeutics focus on?

  Cullinan Therapeutics focuses on Advanced Solid Tumor, Sjogren's Disease, Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) based on our analysis of their pipeline programs and drug development activities.